Kava -241 reduced periodontal destruction in a collagen antibiody primed Porphyromonas gingivalis model of periodontis
Date
2017
Authors
Amar, Salomon
Panek, James
Alshammari, Abdulsalam
Patel, Jayesh
Al-Hashemi, Jacob
Cai, Bin
Huck, Olivier
Version
Accepted manuscript
OA Version
Citation
S. Amar, J. Panek. 2017. "Kava -241 reduced periodontal destruction in a collagen antibiody primed Porphyromonas gingivalis model of periodontis" Journal of Clinical Periodontology, Volume 44, Issue 11, pp.1-10. https://doi.org/10.1111/jcpe.12784
Abstract
AIM: The aim of this study was to evaluate the effect of Kava-241, an optimized Piper methysticum Kava compound, on periodontal destruction in a collagen antibody primed oral gavage model of periodontitis. METHODS: Experimental periodontitis was induced by oral gavage of Porphyromonas gingivalis (P. gingivalis) + type II collagen antibody (AB) in mice during 15 days. Mice were treated with Kava-241 concomitantly or prior to P. gingivalis gavage and compared to untreated mice. Comprehensive histomorphometric analyses were performed. RESULTS: Oral gavage with P. gingivalis induced mild epithelial down-growth and alveolar bone loss, while oral gavage with additional AB priming had greater tissular destruction in comparison with gavage alone (p < .05). Kava-241 treatment significantly (p < .05) reduced epithelial down-growth (72%) and alveolar bone loss (36%) in P. gingivalis+AB group. This Kava-241 effect was associated to a reduction in inflammatory cell counts within soft tissues and an increase in fibroblasts (p < .05). CONCLUSION: Priming with type II collagen antibody with oral gavage is a fast and reproducible model of periodontal destruction adequate for the evaluation of novel therapeutics. The effect of Kava-241 shows promise in the prevention and treatment of inflammation and alveolar bone loss associated with periodontitis. Further experiments are required to determine molecular pathways targeted by this therapeutic agent.